CO5700778A2 - Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular - Google Patents
Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celularInfo
- Publication number
- CO5700778A2 CO5700778A2 CO05045078A CO05045078A CO5700778A2 CO 5700778 A2 CO5700778 A2 CO 5700778A2 CO 05045078 A CO05045078 A CO 05045078A CO 05045078 A CO05045078 A CO 05045078A CO 5700778 A2 CO5700778 A2 CO 5700778A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- heteroaryl
- aryl
- heterocyclic
- cycloalkyl
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title abstract 2
- 229940127089 cytotoxic agent Drugs 0.000 title abstract 2
- 230000004663 cell proliferation Effects 0.000 title 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 125000003118 aryl group Chemical group 0.000 abstract 9
- 125000001072 heteroaryl group Chemical group 0.000 abstract 9
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 8
- 125000000623 heterocyclic group Chemical group 0.000 abstract 8
- 125000003545 alkoxy group Chemical group 0.000 abstract 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- -1 hydroxy, amino, mono-substituted amino Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000006413 ring segment Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42638602P | 2002-11-15 | 2002-11-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5700778A2 true CO5700778A2 (es) | 2006-11-30 |
Family
ID=32326343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO05045078A CO5700778A2 (es) | 2002-11-15 | 2005-05-11 | Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20040152759A1 (enExample) |
| EP (1) | EP1562600A4 (enExample) |
| JP (1) | JP2006508981A (enExample) |
| KR (1) | KR20050086594A (enExample) |
| CN (2) | CN101259131A (enExample) |
| AR (1) | AR042042A1 (enExample) |
| AU (1) | AU2003290943A1 (enExample) |
| BR (1) | BR0315630A (enExample) |
| CA (1) | CA2506308A1 (enExample) |
| CO (1) | CO5700778A2 (enExample) |
| GT (1) | GT200300245A (enExample) |
| MX (1) | MXPA05005150A (enExample) |
| NL (1) | NL1024779C2 (enExample) |
| NO (1) | NO20052578L (enExample) |
| PA (1) | PA8588601A1 (enExample) |
| PE (1) | PE20040835A1 (enExample) |
| PL (1) | PL376954A1 (enExample) |
| RU (1) | RU2342140C2 (enExample) |
| TW (1) | TW200418837A (enExample) |
| UY (1) | UY28081A1 (enExample) |
| WO (1) | WO2004045523A2 (enExample) |
| ZA (1) | ZA200503841B (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100600550B1 (ko) * | 2000-10-20 | 2006-07-13 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
| EP1604665B1 (en) * | 2003-03-10 | 2011-05-11 | Eisai R&D Management Co., Ltd. | C-kit kinase inhibitor |
| JP4303726B2 (ja) | 2003-11-11 | 2009-07-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウレア誘導体およびその製造方法 |
| US7446124B2 (en) * | 2004-07-09 | 2008-11-04 | Prolx Pharmaceuticals Corp. | Wortmannin analogs and methods of using same in combination with chemotherapeutic agents |
| US8969379B2 (en) * | 2004-09-17 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide |
| US20090117197A1 (en) * | 2005-03-21 | 2009-05-07 | Vicus Therapeutics Llc | Compositions and methods for ameliorating cachexia |
| CA2602316A1 (en) * | 2005-03-23 | 2006-09-28 | Pfizer Products Inc. | Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer |
| AU2006245421A1 (en) * | 2005-05-12 | 2006-11-16 | Pfizer Inc. | Anticancer combination therapy using sunitinib malate |
| DK1893213T3 (da) * | 2005-06-03 | 2010-06-07 | Novartis Ag | Kombination af pyrimidylaminobenzamidforbindelser og imatinib til behandling eller forebyggelse af proliferative sygdomme |
| JP5066446B2 (ja) * | 2005-08-01 | 2012-11-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を予測する方法 |
| JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
| CN102716490A (zh) * | 2005-09-01 | 2012-10-10 | 卫材R&D管理有限公司 | 药物组合物的崩解性的改善方法 |
| CN101291950B (zh) * | 2005-09-15 | 2013-01-02 | 科学与工业研究会 | 咪唑基取代的类固醇和茚满-1-酮衍生物 |
| CN101267824A (zh) * | 2005-09-20 | 2008-09-17 | 辉瑞产品公司 | 使用酪氨酸激酶抑制剂的治疗剂型和方法 |
| KR101353763B1 (ko) | 2005-11-07 | 2014-01-21 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 ｃ―ｋｉｔ 키나아제 저해 물질의병용 |
| US20090247576A1 (en) * | 2005-11-22 | 2009-10-01 | Eisai R & D Management Co., Ltd. | Anti-tumor agent for multiple myeloma |
| CN104706637A (zh) * | 2006-05-18 | 2015-06-17 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
| DE102006024834B4 (de) * | 2006-05-24 | 2010-07-01 | Schebo Biotech Ag | Neue Indol-Pyrrol-Derivate und deren Verwendungen |
| US20090203693A1 (en) * | 2006-06-29 | 2009-08-13 | Eisai R & D Management Co., Ltd. | Therapeutic agent for liver fibrosis |
| CN1899616A (zh) * | 2006-07-20 | 2007-01-24 | 中国人民解放军军事医学科学院生物工程研究所 | 非受体酪氨酸激酶c－Abl特异性抑制剂的新用途 |
| JP5368096B2 (ja) | 2006-08-28 | 2013-12-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 未分化型胃癌に対する抗腫瘍剤 |
| WO2008093855A1 (ja) | 2007-01-29 | 2008-08-07 | Eisai R & D Management Co., Ltd. | 未分化型胃癌治療用組成物 |
| US20090004213A1 (en) * | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| CA2704000C (en) | 2007-11-09 | 2016-12-13 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
| US7855204B2 (en) * | 2008-01-22 | 2010-12-21 | Concert Pharmaceuticals Inc. | Derivatives of gefitinib |
| WO2009096377A1 (ja) * | 2008-01-29 | 2009-08-06 | Eisai R & D Management Co., Ltd. | 血管阻害物質とタキサンとの併用 |
| EP2318364A2 (en) * | 2008-07-02 | 2011-05-11 | Generics [UK] Limited | Preparation of 3-pyrrole substituted 2-indolinone derivatives |
| US20100143295A1 (en) * | 2008-12-05 | 2010-06-10 | Auspex Pharmaceuticals, Inc. | Quinazoline inhibitors of egfr tyrosine kinase |
| CA2771403C (en) | 2009-08-19 | 2015-02-24 | Eisai R&D Management Co. Ltd. | Quinoline derivative-containing pharmaceutical composition |
| CN102958523B (zh) | 2010-06-25 | 2014-11-19 | 卫材R&D管理有限公司 | 使用具有激酶抑制作用的组合的抗肿瘤剂 |
| WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
| AU2012246490B2 (en) | 2011-04-18 | 2016-08-04 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
| JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
| CN103127096B (zh) * | 2011-12-02 | 2015-11-25 | 杨子娇 | 吡咯基取代的吲哚类化合物在治疗青光眼病的应用 |
| WO2013152193A2 (en) * | 2012-04-04 | 2013-10-10 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating proliferative disorders with malate or derivatives thereof |
| JPWO2014098176A1 (ja) | 2012-12-21 | 2017-01-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体のアモルファス及びその製造方法 |
| CA2912219C (en) | 2013-05-14 | 2021-11-16 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| EP3187491A4 (en) | 2014-08-28 | 2018-08-01 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| US20180028662A1 (en) | 2015-02-25 | 2018-02-01 | Eisai R&D Management Co., Ltd. | Method for Suppressing Bitterness of Quinoline Derivative |
| KR20240064733A (ko) | 2015-03-04 | 2024-05-13 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| CA2988707C (en) | 2015-06-16 | 2023-10-10 | Eisai R&D Management Co., Ltd. | Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer |
| CN108135894B (zh) | 2015-08-20 | 2021-02-19 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
| CN109311811B (zh) * | 2016-06-09 | 2022-09-09 | 有机合成药品工业株式会社 | 4-(哌啶-4-基)吗啉的制备方法 |
| CN110072528B (zh) | 2017-02-08 | 2022-04-26 | 卫材R&D管理有限公司 | 治疗肿瘤的药物组合物 |
| WO2018212202A1 (en) | 2017-05-16 | 2018-11-22 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
| CN114585389A (zh) * | 2019-09-26 | 2022-06-03 | 星法马私人有限公司 | 治疗性树枝状大分子 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0654024A1 (en) * | 1992-08-06 | 1995-05-24 | Warner-Lambert Company | 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties |
| KR100743287B1 (ko) * | 1998-05-29 | 2007-07-26 | 수젠, 인크. | 피롤기로 치환된 2-인돌리논 단백질 인산화 효소 억제제 |
| JP5336686B2 (ja) * | 1999-11-24 | 2013-11-06 | スージェン， インク． | 遊離酸または遊離塩基としてイオン化可能な医薬品のための処方 |
| CA2395461C (en) * | 1999-12-22 | 2010-05-25 | Sugen, Inc. | Methods of modulating c-kit tyrosine kinase function with indolinone compounds |
| HRP20020751B1 (hr) * | 2000-02-15 | 2011-01-31 | Sugen | Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze |
| MY128449A (en) * | 2000-05-24 | 2007-02-28 | Sugen Inc | Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| AR042586A1 (es) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
| US6797725B2 (en) * | 2001-04-09 | 2004-09-28 | Sugen, Inc. | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
-
2003
- 2003-11-13 AR ARP030104194A patent/AR042042A1/es unknown
- 2003-11-14 JP JP2004553729A patent/JP2006508981A/ja not_active Withdrawn
- 2003-11-14 PE PE2003001154A patent/PE20040835A1/es not_active Application Discontinuation
- 2003-11-14 PA PA20038588601A patent/PA8588601A1/es unknown
- 2003-11-14 TW TW092132030A patent/TW200418837A/zh unknown
- 2003-11-14 AU AU2003290943A patent/AU2003290943A1/en not_active Abandoned
- 2003-11-14 MX MXPA05005150A patent/MXPA05005150A/es unknown
- 2003-11-14 BR BR0315630-3A patent/BR0315630A/pt not_active IP Right Cessation
- 2003-11-14 GT GT200300245A patent/GT200300245A/es unknown
- 2003-11-14 NL NL1024779A patent/NL1024779C2/nl not_active IP Right Cessation
- 2003-11-14 RU RU2005118417/14A patent/RU2342140C2/ru not_active IP Right Cessation
- 2003-11-14 CN CNA2008100814220A patent/CN101259131A/zh active Pending
- 2003-11-14 EP EP03783527A patent/EP1562600A4/en not_active Withdrawn
- 2003-11-14 CA CA002506308A patent/CA2506308A1/en not_active Abandoned
- 2003-11-14 PL PL376954A patent/PL376954A1/pl not_active Application Discontinuation
- 2003-11-14 WO PCT/US2003/036526 patent/WO2004045523A2/en not_active Ceased
- 2003-11-14 US US10/712,296 patent/US20040152759A1/en not_active Abandoned
- 2003-11-14 KR KR1020057008541A patent/KR20050086594A/ko not_active Ceased
- 2003-11-14 UY UY28081A patent/UY28081A1/es not_active Application Discontinuation
- 2003-11-14 CN CNB200380103225XA patent/CN100430060C/zh not_active Expired - Fee Related
-
2005
- 2005-05-11 CO CO05045078A patent/CO5700778A2/es not_active Application Discontinuation
- 2005-05-12 ZA ZA200503841A patent/ZA200503841B/en unknown
- 2005-05-27 NO NO20052578A patent/NO20052578L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL376954A1 (pl) | 2006-01-09 |
| UY28081A1 (es) | 2004-06-30 |
| CN101259131A (zh) | 2008-09-10 |
| GT200300245A (es) | 2004-06-23 |
| NL1024779A1 (nl) | 2004-05-18 |
| KR20050086594A (ko) | 2005-08-30 |
| NO20052578L (no) | 2005-05-27 |
| ZA200503841B (en) | 2006-09-27 |
| WO2004045523A3 (en) | 2004-09-30 |
| RU2005118417A (ru) | 2006-01-20 |
| US20040152759A1 (en) | 2004-08-05 |
| JP2006508981A (ja) | 2006-03-16 |
| CN100430060C (zh) | 2008-11-05 |
| MXPA05005150A (es) | 2005-07-22 |
| TW200418837A (en) | 2004-10-01 |
| EP1562600A4 (en) | 2008-06-25 |
| EP1562600A2 (en) | 2005-08-17 |
| AR042042A1 (es) | 2005-06-08 |
| CN1711089A (zh) | 2005-12-21 |
| PE20040835A1 (es) | 2004-11-18 |
| BR0315630A (pt) | 2005-08-23 |
| CA2506308A1 (en) | 2004-06-03 |
| AU2003290943A1 (en) | 2004-06-15 |
| PA8588601A1 (es) | 2004-05-21 |
| NL1024779C2 (nl) | 2004-11-09 |
| WO2004045523A2 (en) | 2004-06-03 |
| RU2342140C2 (ru) | 2008-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR042042A1 (es) | Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular | |
| PA8593001A1 (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| CO5640118A2 (es) | 5,7-diaminopirazol[4,3-d]piridinas utiles en el tratamiento de la hipertension | |
| PE20060185A1 (es) | ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA | |
| PE20170003A1 (es) | Compuestos heterociclicos y usos de los mismos | |
| AR092490A2 (es) | Indolil alquil amino derivados sustituidos como inhibidores de la histona desacetilasa | |
| PE20060842A1 (es) | Amino-imidazolonas para la inhibicion de b-secretasa | |
| PE20080928A1 (es) | Derivados de anilinopiperazina como inhibidores de proteina quinasa | |
| PE20080067A1 (es) | DERIVADOS DE TRIAZOLOPIRAZINA COMO MODULADORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO DE HEPATOCITO (c-MET O HGFR) | |
| CO6270320A2 (es) | Derivados de piperidina utiles como antagonistas del receptor orexina | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| PE20040197A1 (es) | Pirazolopiridinas sustituidas con carbamato | |
| AR044874A1 (es) | Derivados de 4- cianopirazol-3 - carboxamida, su preparacion y su aplicacion en terapeutica | |
| PE20090648A1 (es) | Compuestos para el tratamiento de la hepatitis c | |
| PE20060570A1 (es) | Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10 | |
| AR118123A2 (es) | Derivados de isoxazolidina, proceso para preparar dichos compuestos, composición farmacéutica y combinación | |
| AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
| UY28333A1 (es) | Inhibidores de caspasa y sus usos. | |
| CO5680412A2 (es) | Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino | |
| AR073043A1 (es) | Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras. | |
| PA8587501A1 (es) | Benzoxazinonas sustituidas y usos de las mismas | |
| GT200100251A (es) | Procedimiento para la preparacion de imidazotriazinonas substituidas con sulfonamida | |
| CO5690551A2 (es) | Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo | |
| PE20050336A1 (es) | Compuestos triciclicos como inhibidores de la proteina farnesil transferasa | |
| CR8749A (es) | Derivados de pirimidina para tratar el crecimiento celular anomalo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |